Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
The Chemours Company reported Q2 2026 net sales of $1.591 billion and a net loss attributable to Chemours of $274 million, or $1.81 per basic and diluted share. For the first six months of 2026, net sales were $2.972 billion and the net loss was $303 million.
Thermal & Specialized Solutions generated $591 million of Q2 net sales and Titanium Technologies $661 million. Operating cash flow for the first half of 2026 was $114 million, while purchases of property, plant, and equipment totaled $93 million.
At June 30, 2026, Chemours reported total assets of $7.150 billion, total current liabilities of $1.861 billion, long‑term debt of $3.838 billion and total Chemours stockholders’ equity of $(49) million. The company held $671 million of unrestricted cash and had $953 million available under its revolving credit facility, and stated it believes it has sufficient liquidity to timely settle its current liabilities through at least the end of August 2027, although adverse outcomes in legal or environmental matters could have a material adverse effect on liquidity. Chemours also revised certain 2025 figures for immaterial errors primarily related to the timing of income tax expense recognition.
The Chemours Company reported Q2 2026 results with net sales of $1.59 billion, down 1% year over year, and a net loss of $274 million ($1.81 per share), narrower than a $380 million loss a year earlier. Adjusted net income was $64 million and Adjusted EBITDA $247 million, both below prior‑year levels.
Free cash flows rose to $114 million from $50 million, lifting the free cash flow conversion rate to 46% and contributing to a net leverage ratio of 4.4x on a trailing twelve‑month Adjusted EBITDA basis. Consolidated gross debt was $3.9 billion and total liquidity was $1.6 billion, including $671 million of unrestricted cash and $953 million of revolver capacity.
Thermal & Specialized Solutions delivered $591 million of sales and a 36% Adjusted EBITDA margin, aided by pricing despite softer Opteon™ aftermarket demand. Titanium Technologies saw modest sales and EBITDA gains from TiO2 price increases, while Advanced Performance Materials experienced lower sales and a 48% EBITDA decline, offset by strong growth in Performance Solutions serving data center and semiconductor markets.
Results reflected significant litigation and environmental charges related to PFAS matters and settlements, partly offset by a gain on Kuan Yin land sales. For full‑year 2026, Chemours projects 1–5% net sales growth, $775–$825 million Adjusted EBITDA, free cash flow conversion above 25%, and a net leverage ratio of around 3.8x by year‑end.
Chemours Co reports that President, Advanced Performance Materials, Familiar Calderon Gerardo had 943 shares of common stock automatically withheld on August 1, 2026 to satisfy tax obligations on vesting restricted stock units and dividend equivalent units.
No shares were sold in the market, and holdings after the withholding were 58,498.8899 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President, Thermal & Specialized Solutions, had 663 shares of common stock automatically withheld on 2026-08-01 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state this was a tax-withholding disposition and that no shares were sold. After this event, Martinko holds a total of 54,818.5559 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co director and Chief Executive Officer Denise Dignam reported a tax-withholding disposition of 477 shares of common stock on August 1, 2026 at $16.61 per share. Shares were automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; no shares were sold. Following this withholding, she reported 337,492.9016 shares held directly, including restricted stock units and dividend equivalent units.
Chemours Co reported that SVP, GC & Corp. Secretary Kristine M. Wellman had 391 shares of common stock automatically withheld on August 1, 2026 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state that no shares were sold, and her direct holdings, including shares, restricted stock units and dividend equivalent units, total 74,418.8998 shares after this transaction.
Chemours Co director Courtney Mather received a grant of deferred stock units as part of board compensation. On this date, Mather acquired 1,401 deferred stock units, each economically equivalent to one share of Chemours common stock, at a reference value of $20.52 per unit.
The award increases Mather’s directly held deferred stock units to a total of 8,983.8481 units, including dividend equivalent units. These deferred stock units become payable in shares of common stock in the first month after Mather’s termination of service as a director, so they function as long-term, non-cash compensation rather than an open-market purchase.
The Chemours Company entered into a proposed settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims relating to PFAS emissions and other alleged activities at several facilities. Chemours agreed to pay a $22.5 million civil penalty in three annual installments, beginning within 30 days after court approval of a Consent Decree, and to fund $90 million of additional mitigation projects over 15 years to reduce PFAS emissions and support alternative drinking water solutions.
The company will expand off-site drinking water programs in West Virginia, Ohio and New Jersey, which it expects will increase existing environmental reserves. Chemours also resolved litigation brought by the West Virginia Rivers Coalition for less than $1 million. The settlement, which does not constitute an admission of liability or fault by Chemours, remains subject to public notice, comment and final court approval.
CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.
Chemours Co director Mary B. Cranston received an equity grant of 7,182 shares of common stock on May 6. The award was granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase.
After this grant and an adjustment to correct an administrative error in prior filings, her direct and deferred holdings now total 106,830.0129 shares, including deferred stock units and related dividend equivalent units.
Chemours director Leslie M. Turner received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. The units were awarded at no cash cost and increase Turner’s direct holdings to 24,603.3891 stock units.
According to the footnotes, these stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Turner separates from service on the Board. This reflects routine equity-based board compensation rather than an open-market purchase.